$CPSH HybridTech Armor® Strike Plates Undergoing U.S. Navy Sea Trials

NORTON, Mass., Dec. 04, 2017  — CPS Technologies Corporation (Nasdaq:CPSH) is pleased to announce that a jointly-developed integrated armor solution incorporating CPS’ HybridTech Armor® is now undergoing sea trials for a key U.S. Navy requirement.

After several years of joint development, with original funding from a Navy SBIR, prime contractor Kinetic Protection has delivered an integrated armor solution to the U.S. Navy, incorporating and based upon CPS’ HybridTech Armor strike faces, which meets the exacting requirements of ballistic protection, light weight, cost and durability for this Navy application.  The primary objective of the current sea trials, which will last into 2018, is to confirm environmental durability.

The Kinetic Protection partnership is a primary example of CPS’ strategy of teaming with multiple armor integrators worldwide to develop integrated armor solutions which are enabled by the remarkable properties of CPS’ HybridTech Armor. These solutions are comprised of several layers of material integrated together with HybridTech Armor strike faces. The HybridTech Armor itself consists of ceramic tiles completely enveloped and mechanically and chemically bonded to lightweight and stiff aluminum metal matrix composites.

Tom Breen, CPS Technologies Senior VP of Sales and Marketing, commented, “CPS Technologies HybridTech Armor components result in a remarkably lighter armor than traditional steel offerings. Using our patented, metal-encapsulated solution enhances state of the art ceramic performance while also providing superior, yet cost effective environmental durability that is measured in decades instead of years. Our modular designs have been field tested and proven to defeat threats as high as STANAG 6. CPS has an excellent track record supporting multiple branches of the US Military as well as domestic and international prime contractors and armor integrators. Working with technology innovators such as Kinetic Protection, LLC., continues that long string of successes.”

Kinetic Protection’s President Erik Crawford adds, “Kinetic Protection has been identifying and delivering real-world anti-terror/force-protection solutions for our customers through the years and the demands are high.  We in part have been able to achieve this through valued and vital partnerships with the likes of CPS Technologies.  This is very much a contact sport, and we are thrilled to take the field with CPS on our team!”

About CPS Technologies Corporation:
CPS is a global leader in producing metal-matrix composite components used to improve the reliability and performance of various armor and electrical systems. CPS products are used to defeat the most advanced threats to ground, airborne and naval platforms. They are also used in motor controllers for hybrid and electric vehicles, high-speed trains, subway cars and wind turbines, as well as heat spreaders in internet switches, routers and high-performance microprocessors.

About Kinetic Protection, LLC.:
Based in Stillwater, MN, Kinetic Protection develops and manufactures advanced defense systems for the US military. The company offers its customers a diversified array of innovative solutions at the leading edge of global technology.  With over 20 years of peacetime and wartime experience, Kinetic Protection has hand-selected former operators and decision-makers in several disciplines to leverage current and emerging technology and combine the understanding of operational procedures and needs.

CPS Technologies Corporation
Ralph Norwood, Chief Financial Officer
111 South Worcester Street
Norton, MA 02766
Telephone: (508) 222-0614
Web Site:  www.alsic.com

$RETO Announces Full Exercise of the Underwriter’s Over-Allotment Option

BEIJING

ReTo Eco-Solutions, Inc. (NASDAQ:RETO) (“ReTo” or the “Company”), a manufacturer and distributor of eco-friendly construction materials as well as equipment used for the production of these eco-friendly construction materials, and consultation, design, project implementation and construction of urban ecological environments including those for the purpose of capturing, controlling and reusing rainwater, commonly called “sponge cities”, today announced that ViewTrade Securities, Inc., who acted as the managing underwriter and sole book-runner of the Company’s initial public offering (“IPO”), has exercised the full over-allotment option to purchase an additional 420,000 common shares at the IPO price of $5.00 per share. As a result, the Company has raised gross proceeds of approximately $2,100,000, in addition to the previously announced IPO gross proceeds of approximately $14 million, before underwriting discounts and commissions and offering expenses.

A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on November 28, 2017. The offering has been made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained, when available, from ViewTrade Securities, via email: IB@Viewtrade.com or standard mail at ViewTrade Securities, 7280 W Palmetto Park Rd, #310, Boca Raton, FL 33433, Attn: Prospectus Department. In addition, a copy of the final prospectus relating to the offering may be obtained via the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Reto Eco-Solutions, Inc.

Founded in 1999 and headquartered in Beijing, ReTo is a manufacturer and distributor of eco-friendly construction materials (aggregates, bricks, pavers and tiles), made from mining waste (iron tailings) and fly-ash, as well as equipment used for the production of these eco-friendly construction materials. The Company also provides a full range of eco-friendly project solutions, including consultation, design, project implementation and construction, relating to all stages of sponge-city projects for customers. The Company’s clients are located in mainland China, and internationally, including Canada, the United States, Mongolia, Middle East, India, South Asia, North Africa and Brazil.

$ASTC Completed Successful 1st Detect Demo with DHS and TSA Personnel

AUSTIN, Texas

Astrotech Corporation (NASDAQ: ASTC) is excited to announce that – following a successful demonstration with Department of Homeland Security (DHS) and Transportation Security Administration (TSA) personnel – 1^st Detect’s TRACER 1000 MS-ETD will be available for demonstration at Astrotech’s annual meeting of shareholders, to be held on Dec. 7, 2017 at 9:00 a.m. CT at the JW Marriott, 110 E. 2^nd St., Austin, TX.

The TRACER 1000 is a mass spectrometry-based explosives trace detector (ETD), custom-developed for the TSA as an improvement over and replacement for the ion mobility spectrometry (IMS) ETD systems currently deployed at aviation checkpoints worldwide.

These antiquated IMS systems have many shortcomings – most notably their limited library of detectable compounds, inability to adapt to emerging threats, and significant false positive rates that extend security wait times. The TRACER 1000 overcomes all of these shortcomings, and also provides significant enhancements, including:

• Considerably expanded list of explosives, narcotics and other compounds of interest;
• Target library that can be instantaneously updated or expanded in the field without requiring hardware configuration changes;
• Near-zero false positive rates;
• Improved passenger satisfaction due to increased throughput at checkpoints; and
• Similar market cost to current IMS ETDs.

“We believe the TRACER 1000 will address the TSA’s current and future ETD needs, and we are excited to begin testing with the Department of Homeland Security’s Transportation Security Laboratory in the coming weeks,” said Thomas B. Pickens III, CEO of 1^st Detect and Astrotech. “The TRACER 1000 will significantly augment airport security by resolving the problems the TSA has with current IMS-based ETD systems. The demonstration of the TRACER 1000 at our annual meeting will showcase the results of years of investment, dedicated hard work, and numerous technological breakthroughs to enhance our nation’s security.”

About Astrotech

Astrotech Corporation (NASDAQ: ASTC) is an innovative science and technology company that invents, acquires, and commercializes technological innovations sourced from research institutions, laboratories, universities, and internally, and then funds, manages, and builds proprietary, scalable start-up companies for profitable divestiture to market leaders to maximize shareholder value. Sourced from Oak Ridge Laboratory’s chemical analyzer research, 1^st Detect develops, manufactures, and sells chemical analyzers for use in the security, defense, healthcare, food and beverage, and environmental markets. Sourced from decades of image research from the laboratories of IBM and Kodak, Astral Images sells film-to-digital image enhancement, defect removal and color correction software, and post processing services providing economically feasible conversion of television and feature 35mm and 16mm films to the new 4K ultra-high definition (UHD), high-dynamic range (HDR) format necessary for the new generation of digital distribution. Sourced from NASA’s extensive microgravity research, Astrogenetix is applying a fast-track, on-orbit discovery platform using the International Space Station to develop vaccines and other therapeutics. Demonstrating its entrepreneurial strategy, Astrotech management sold its state-of-the-art satellite servicing operations to Lockheed Martin in August 2014. Astrotech has operations throughout Texas and is headquartered in Austin. For information, please visit www.astrotechcorp.com.

This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, whether we can successfully develop our proprietary technologies and whether the market will accept our products and services, as well as other risk factors and business considerations described in the Company’s Securities and Exchange Commission filings including the annual report on Form 10-K. Any forward-looking statements in this document should be evaluated in light of these important risk factors. The Company assumes no obligation to update these forward-looking statements.

$DPW Subsidiary Coolisys Technologies Unveils Its First Cryptocurrency Hardware

Targets Popular Antminer Model S9 to Launch Power Product Line for Digital Miners

FREMONT, Calif., Dec. 04, 2017  — Digital Power Corporation (NYSE.American:DPW) (“Digital Power” or the “Company“), a company seeking to increase revenues through acquisitions and organic growth, announced today that its wholly owned subsidiary, Coolisys Technologies, Inc. (”Coolisys”), anticipates launching a line of advanced technology power systems for digital mining of cryptocurrencies, including Bitcoin and the other top digital currencies worldwide. Both digital mining as an industry and cryptocurrency as an asset class have experienced exponential growth for the past 5 years. Leveraging the Company’s 48 years of designing, manufacturing and receiving worldwide adoption of its highly efficient and durable power solutions and systems, Coolisys believes it is well positioned to resolve challenges with the cost and use of power for today’s burgeoning digital mining community and adopt and implement other technological improvements.

Coolisys stated that the first miner AC-DC switching power supply being produced will be for use by the Antminer S9 model by Bitmain Masters and can now be pre-ordered. The very popular and highly regarded Antminer S9 was the world’s first dedicated bitcoin miner using an application-specific integrated circuit, (commonly known as an ’ASIC’), based on the sixteen nanometer (“16nm”) process on its system. Coolisys noted the new product line was a result of the agreement with PoW Digital Mining previously announced on August 10, 2017, which said ‘PoW Digital Mining is to lead its development of an equipment and services portfolio targeting Digital Mining and related research and development of cryptocurrency. The active digital mining markets led by Bitcoin, Ethereum and the other 900+ digital currencies have created a budding hardware demand driving the need for efficient low-cost power solutions.’ PoW Digital Mining affirmed that the top issue for most professionals and amateurs who actively mine Bitcoin, Litecoin and other cryptocurrencies is energy costs. Cryptocurrency mining of block-chain transactions is power-hungry. The most successful miners are those that get the highest hash rates out of their systems, at the lowest total cost. Since electricity is the biggest on-going cost of mining, it follows that maximizing the efficiency of the power supply is critical. Even with the smallest of efficiencies delivering notable savings, PoW Digital Mining reported that a new line of crypto-mining power solutions within a suite of products could be readily commercialized.

Amos Kohn, President and CEO of Coolisys Technologies and Digital Power Corporation stated, “We have a competitive advantage given our expertise in developing and providing advance power solutions for the tech, military, industrial and healthcare sectors. To power the AntMiner S9, we will utilize our field-proven platform, previously implemented to power cloud-based computing networks and servers, that employ highly-efficient power switching with fully synchronous rectification and advanced digital signal processing (DSP). Our power solutions are based on next-generation design and we believe are among the most technologically advanced power processing solutions available. We project our cryptocurrency initiatives and products could have a material effect on the Company’s revenues and net income for this component of its operations during 2018. We look forward to presenting what we are developing.”

“When we first met with the Digital Power in 2016 and were becoming familiar with its long history of manufacturing advanced power solutions, we recognized that the Company was underutilizing its technical knowledge base and product development capabilities. Our investment strategy included our looking forward to harnessing and leveraging these assets to provide a range of new product portfolios and expanding the Company’s revenue streams. We look forward over the coming months that the marketplace will continue to appreciate the abilities and potential of DPW, its management and staff and its strategies to bring added-value to our shareholders,” commented Milton “Todd” Ault, III, the Company’s Executive Chairman.

Units may be pre-ordered at www.SuperCryptoPower.com with units shipping some time during the first quarter of 2018.

The Company reminds its shareholders, investors and the public it will issue an investor update before the opening of the market on the morning of December 7, 2017. Topics will include an update on revenue guidance for the quarter and 2018, a progress report on the cryptocurrency initiatives by Coolisys Technologies, advances made on the MTIX $50M purchase order and the advanced technology platform and an update on Digital Power Lending.

ABOUT DIGITAL POWER

Headquartered in Fremont, CA, Digital Power Corporation, through its subsidiaries, designs, manufactures and sells high-grade customized and off-the-shelf power system solutions. Our products are used in the most demanding communications, industrial, medical and military applications where customers demand high density, high efficiency and rugged power solutions. The Company’s wholly owned subsidiary, Coolisys Technologies, Inc., is dedicated to providing world-class technology-based solutions where innovation is the main driver for mission-critical applications and lifesaving services. Coolisys’ growth strategy targets core markets that are characterized by “high barriers to entry” and include specialized products and services not likely to be commoditized. Coolisys Technologies, Inc., a developer and manufacturer that services the defense, aerospace, medical and industrial sectors, has three subsidiaries including Digital Power Limited dba Gresham Power Ltd., www.GreshamPower.com, a manufacturer based in Salisbury, UK.; Microphase Corporation, www.MicroPhase.com with its headquarters in Shelton, CT 1-203-866-8000; and Power-Plus Technical Distributors, www.Power-Plus.com, a wholesale distributor based in Sonora, CA 1-800-963-0066.

Digital Power Lending, LLC, is a wholly owned subsidiary of the Company, is based in Fremont, CA, and is a California private lending company dedicated to strategically providing capital to small and middle size businesses for an equity interest in addition to loan fees and interest, www.DigitalPowerLending.com. Excelo, LLC, a wholly-owned subsidiary of the Company, is a national search firm specializing in fulfilling strategic executive, professional and hi-tech placements for businesses delivering world-class services, www.Excelo.com. Digital Power Corporation’s headquarters is located at 48430 Lakeview Blvd., Fremont, California, 94538; 1-877-634-0982; www.DigiPwr.com.

For Investor inquiries: IR@digipwr.com, www.DigitalPowerCorp.com or 1-888-753-2235.

Forward-Looking Statements

The foregoing release contains “forward looking statements” regarding future events or results within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements concerning the Company’s current expectations regarding revenues for the remaining 2017 and thereafter from contracts and operations on a consolidated basis, the ability of the Company to complete the manufacturing of its new product line for the digital mining community or the ability of the Company to sell digital mining power systems. The Company cautions readers that such “forward looking statements” are, in fact, predictions that are subject to risks and uncertainties and that actual events or results may differ materially from those anticipated events or results expressed or implied by such forward- looking statements. The Company disclaims any current intention to update its “forward looking statements,” and the estimates and assumptions within them, at any time or for any reason, unless required by applicable law. More information, including potential risk factors, that could affect the Company’s business and financial results are included in the Company’s filings with the U.S. Securities and Exchange Commission, including, but not limited to, the Company’s Forms 10-K, 10-Q and 8-K. All filings are available at www.sec.gov and on the Company’s website at www.DigitalPowerCorp.com.

$PRKR Invited to Present Clarifications in German Infringement Case Against $AAPL

Court Rejects Apple’s Request for Bond

JACKSONVILLE, Fla., Dec. 01, 2017 — ParkerVision, Inc. (NASDAQ:PRKR), a developer, manufacturer and marketer of semiconductor technology solutions for wireless applications, announced today that the Munich court rejected the request by Apple, Inc. and certain of its’ subsidiaries that ParkerVision GmbH be required to post a bond as required of a non-German entity. The court has also informed ParkerVision GmbH that it is invited to provide further clarification regarding certain elements of infringement by Apple following the finalization of this decision.

A hearing was held on November 16, 2017 in this case during which both parties were allowed to present arguments regarding the alleged infringement, by Apple, of the German part of European Patent 1 135 853 (“the ‘853 Patent”).

Jeffrey Parker, CEO of ParkerVision, who attended the November 16^th hearing, stated, “I believe our counsel was able to thoroughly explain to the court our energy sampling technology as described in the ‘853 Patent and furthermore, how our energy sampling technology is clearly different from sample-and-hold technologies that the defendant cited as prior art.   Based on comments from the court during the hearing, we believe Apple presented oral arguments that conflicted with their written pre-hearing briefs.”

Parker continued, “We welcome the court’s request for additional information, as we believe further clarification will only strengthen our infringement position and enable the court to reach a swift decision.  We are working with German counsel to expedite the schedule for these next steps and anticipate that the court will continue to move at the same rapid pace that it has thus far.”

 About ParkerVision

ParkerVision, Inc. designs, develops and markets its proprietary radio-frequency (RF) technologies, which enable advanced wireless solutions for current and next generation communications networks. Currently developing several new products to enhance Wi-Fi connectivity for small businesses and consumers, ParkerVision has recently unveiled a family of products under the Milo™ brand that leverages existing Wi-Fi infrastructure to create more optimal Wi-Fi configuration and superior coverage.  For more information please visit www.parkervision.com. (PRKR-G)

Safe Harbor Statement

This press release contains forward-looking information.  Readers are cautioned not to place undue reliance on any such forward-looking statements, each of which speaks only as of the date made.  Such statements are subject to certain risks and uncertainties which are disclosed in the Company’s SEC reports, including the Form 10-K for the year ended December 31, 2016 and the Forms 10-Q for the quarters ended March 31, June 30, and September 30, 2017.  These risks and uncertainties could cause actual results to differ materially from those currently anticipated or projected.

Contact:

Cindy Poehlman
Chief Financial Officer
ParkerVision, Inc.
904-732-6100
cpoehlman@parkervision.com

or

Laurie Little
The Piacente Group
212-481-2050
parkervision@tpg-ir.com

$ADMP Results of a Human Factors Study in Pre-filled Epinephrine at #AAAAI

SAN DIEGO, Dec. 01, 2017 — Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today the acceptance of a presentation entitled “Human Factors Study of A Newly Approved Epinephrine Prefilled Syringe (Symjepi) for the Emergency Treatment of Allergic Reactions (Type I) Including Anaphylaxis”.  The presentation will be for the American Academy of Allergy, Asthma, and Immunology (AAAAI) joint congress with the World Allergy Organization and will be held in Orlando, Florida on March 3, 2018.   This premier annual educational event draws thousands of healthcare professionals including allergists, immunologists and other medical specialists.

Dr. Dennis J. Carlo, President/CEO of Adamis stated, “Symjepi was studied in trained and untrained adults, adolescents and caregivers.  The results definitively showed Symjepi to be an easy to use, small and intuitive device.”  Dr. Ronald Moss, Chief Medical Officer at Adamis and a Fellow of AAAAI stated, “For a layperson, treatment of anaphylaxis with a simple non-threatening device is critical to successful use.”  The presentation will focus on the successful human factors study utilizing Symjepi.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy. The company’s first product, Symjepi (epinephrine) Injection 0.3mg, was approved in June 2017 for use in the emergency treatment of acute allergic reactions, including anaphylaxis.  Adamis’ product pipeline includes HFA metered dose inhaler and dry powder inhaler products for the treatment of bronchospasm and asthma.
The Company’s U.S. Compounding, Inc. (USC) subsidiary, which is registered as a drug compounding outsourcing facility under Section 503B of the U.S. Food, Drug & Cosmetic Act and the U.S. Drug Quality and Security Act, compounds sterile prescription drugs, and certain nonsterile drugs, to patients, physician clinics, hospitals, surgery centers and other clients throughout most of the United States.

Adamis Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements relate to future events or future results of operations, including, but not limited to the following statements: the status of anticipated presentations by the company at upcoming conferences; the company’s beliefs concerning the ability of its products and product candidates to compete successfully in the market; the company’s beliefs concerning the results of studies relating to Symjepi and user perceptions of Symjepi; and the company’s beliefs concerning the safety and effectiveness of its products and product candidates.  These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis’ actual results to be materially different from those contemplated by these forward-looking statements.  Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis’ filings from time to time with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC’s web site at http://www.sec.gov.  Any forward-looking statement in this press release speaks only as of the date on which it is made.  Except to the extent required by law, Adamis expressly disclaims any obligation to update any forward-looking statements.

Contacts:

Mark Flather
Senior Director, Investor Relations
& Corporate Communications
Adamis Pharmaceuticals Corporation
(858) 412-7951
mflather@adamispharma.com

$NTNX to Present at Upcoming Investor Conferences

SAN JOSE, Calif.

Nutanix (NASDAQ: NTNX), a leader in enterprise cloud computing, today announced that its management will be presenting at the following upcoming financial community events:

• Raymond James Technology Investors Conference
  New York, New York
  Monday, December 4, 2017
  1:15 p.m. EST; 10:15 a.m. PST

• 2017 Wells Fargo Tech Summit
  Park City, Utah
  Wednesday December 6, 2017
  11:00 a.m. MST; 1:00 p.m. EST; 10:00 a.m. PST

A live audio webcast and replay of each presentation will be accessible on the Nutanix Investor Relations website at: ir.nutanix.com.

About Nutanix

Nutanix makes infrastructure invisible, elevating IT to focus on the applications and services that power their business. The Nutanix Enterprise OS Cloud Software leverages web-scale engineering and consumer-grade design to natively converge compute, virtualization and storage into a resilient, software-defined solution with rich machine intelligence. The result is predictable performance, cloud-like infrastructure consumption, robust security, and seamless application mobility for a broad range of enterprise applications and services. Learn more at www.nutanix.com or follow us on Twitter @nutanix.

© 2017 Nutanix, Inc. All rights reserved. Nutanix, the Enterprise Cloud Platform, and the Nutanix logo are trademarks of Nutanix, Inc., registered or pending registration in the United States and other countries. All other brand names mentioned herein are for identification purposes only and may be the trademarks of their respective holder(s).

Media Contact
Nutanix, Inc.
Tonya Chin, (408) 505-4637
tonya@nutanix.com

$GEOS Lemelson Capital Management Announces 10 Percent Stake

Firm reiterates near-term intrinsic value at $38 per share

MARLBOROUGH, Mass., Dec. 1, 2017 — Lemelson Capital Management, LLC, a private investment management firm, announced today it has acquired, for its flagship Amvona Fund, LP, a stake of approximately 10 percent in shares of Geospace Technologies (NASDAQ: GEOS), a global leader in the design and manufacture of instruments and equipment used by the oil and gas industry. In addition, it is urging the company to initiate an immediate share repurchase plan.

“With oil prices at a two-year high and rising and an agreement by OPEC and other major producers to extend output curbs until the end of 2018, the market continues to radically under-value Geospace Technologies. This overlooks the firm’s technological leadership—the company’s state-of-the-art GCL and GSX product lines have no competitive analogue; as well as its $75 million in liquidity, understated assets, zero-debt balance sheet and substantial revenue growth,” said Fr. Emmanuel Lemelson, Chief Investment Officer of Lemelson Capital Management.

With revenue in the fourth quarter increasing 45% over last year’s fourth quarter and representing the highest quarterly revenue in more than two years, a near 15-fold year-over-year increase in sales of the company’s market-leading GSX wireless recording system, a 61 percent increase in wireless product revenue in 2017 compared to fiscal year 2016 and operating income associated with the company’s non-seismic products increasing each year over the last three consecutive years, Lemelson Capital Management believes the near-term intrinsic value of Geospace Technologies common stock to be at least $38 per share.¹

“Geospace Technologies continues to experience significant increases in revenues and liquidity as evidenced by the more than $10 million in cash provided by operating activities in fiscal year 2017,” Lemelson added. “We believe the company’s non-cash charges², including aggressive inventory write-downs and subsequent sales of these same depreciated inventories at significant profits represent a tremendous store of shareholder value which is not reflected on the company’s balance sheet and points to the need for an immediate and aggressive share buyback program.”

Lemelson Capital today also released a copy of a recent letter sent to the company’s board of directors regarding this and other proposed actions. A copy of the letter can be found here: https://www.scribd.com/document/355452065/Letter-to-Gary-Owen-BoD-Geospace-Technologies-Corporation-NASDAQ-GEOS

About Lemelson Capital Management

Lemelson Capital Management, LLC is a private investment management firm focused on deep value and special situation investments. For more information, see: http://www.lemelsoncapital.com

For further information, please contact:

Media and Public Relations
Lemelson Capital Management, LLC

Telephone: 508-630-2281

SPECIAL NOTE REGARDING THIS RELEASE

THIS REPORT INCLUDES INFORMATION BASED ON DATA FOUND IN FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION, INDEPENDENT INDUSTRY PUBLICATIONS AND OTHER SOURCES. ALTHOUGH WE BELIEVE THAT THE DATA IS RELIABLE, WE HAVE NOT SOUGHT, NOR HAVE WE RECEIVED, PERMISSION FROM ANY THIRD-PARTY TO INCLUDE THEIR INFORMATION IN THIS PRESENTATION. MANY OF THE STATEMENTS IN THIS PRESENTATION REFLECT OUR SUBJECTIVE BELIEF.

EMMANUEL LEMELSON’S VIEWS AND HIS HOLDINGS OF THE SECURITIES MENTIONED IN THIS RELEASE COULD CHANGE AT ANY TIME. HE MAY SELL ANY OR ALL OF HIS HOLDINGS OR INCREASE HIS HOLDINGS BY PURCHASING ADDITIONAL SECURITIES. HE MAY TAKE ANY OF THESE OR OTHER ACTIONS REGARDING ANY OF SUCH SECURITIES WITHOUT UPDATING THIS RELEASE OR PROVIDING ANY NOTICE WHATSOEVER OF ANY SUCH CHANGES.

THE INFORMATION CONTAINED ABOVE IS NOT AND SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, AND DOES NOT PURPORT TO BE AND DOES NOT EXPRESS ANY OPINION AS TO THE PRICE AT WHICH THE SECURITIES OF GEOSPACE TECHNOLOGIES MAY TRADE AT ANY TIME. THE INFORMATION AND OPINIONS PROVIDED ABOVE SHOULD NOT BE TAKEN AS SPECIFIC ADVICE ON THE MERITS OF ANY INVESTMENT DECISION. INVESTORS SHOULD MAKE THEIR OWN DECISIONS REGARDING GEOSPACE TECHNOLOGIES AND ITS PROSPECTS BASED ON SUCH INVESTORS’ OWN REVIEW OF PUBLICALLY AVAILABLE INFORMATION AND SHOULD NOT RELY ON THE INFORMATION CONTAINED ABOVE. NEITHER LEMELSON CAPITAL MANAGEMENT, LLC NOR ANY OF ITS AFFILIATES ACCEPTS ANY LIABILITY WHATSOEVER FOR ANY DIRECT OR CONSEQUENTIAL LOSS HOWSOEVER ARISING, DIRECTLY OR INDIRECTLY, FROM ANY USE OF THE INFORMATION CONTAINED ABOVE.

FORWARD-LOOKING STATEMENTS

Certain statements contained in this letter are forward-looking statements including, but not limited to, statements that are predications of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties. Forward-looking statements are not guarantees of future performance or activities and are subject to many risks and uncertainties. Due to such risks and uncertainties, actual events or results or actual performance may differ materially from those reflected or contemplated in such forward-looking statements. Forward-looking statements can be identified by the use of the future tense or other forward-looking words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “should,” “may,” “will,” “objective,” “projection,” “forecast,” “management believes,” “continue,” “strategy,” “position” or the negative of those terms or other variations of them or by comparable terminology. Important factors that could cause actual results to differ materially from the expectations set forth in this letter include, among other things, the factors identified under the section entitled “Risk Factors” in Geospace Technologies Annual Report on Form 10-K for the year ended September 30, 2016. Such forward-looking statements should therefore be construed in light of such factors, and Lemelson Capital is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

¹ Lemelson Capital believes the intrinsic value of Geospace Technologies is likely in the $50 to $60 per share range over the next few years
² Non-cash adjustments for inventory obsolescence and impairment charges on factory equipment alone  amounted to $26.8 million in fiscal year 2017

$CASI ENMD-2076 Poster Presentation at #SABCS, Triple-Negative Breast Cancer

ROCKVILLE, Md., Dec. 1, 2017  — CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs announces a poster presentation on ENMD-2076 at the 2017 San Antonio Breast Cancer Symposium^TM (SABCS), December 5-9, 2017 in San Antonio, Texas.

ENMD-2076 is currently in a Phase 2 trial for the treatment of triple-negative breast cancer (TNBC) at two locations in the U.S. The poster will be presented in the session listed below and will be available on the CASI Pharmaceuticals website after the conclusion of the presentation.

Program Number: PD3-16
Abstract Number: 272
Session Title: Novel Drugs / Predicting Response for HER2+ Breast Cancer
Session Date: Thursday, December 7, 2017
Session Time: 7:00:00 AM – 9:00:00 AM CST
Title: “Clinical Safety and Efficacy of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated, Locally Advanced or Metastatic Triple-Negative Breast Cancer”

About CASI Pharmaceuticals, Inc.

CASI is a U.S. based, late-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a focus on commercialization in China. CASI’s product pipeline features (1) EVOMELA^®, MARQIBO^® and ZEVALIN^®, all U.S. Food and Drug Administration (FDA) approved drugs in-licensed from Spectrum Pharmaceuticals, Inc. for China regional rights, and currently in various stages in the regulatory and clinical process for market approval in China, (2) CASI-001 and CASI-002, proprietary preclinical candidates in immune-oncology, and (3) our proprietary drug candidate, ENMD-2076, ongoing in one Phase 2 clinical study. CASI is headquartered in Rockville, Maryland and has a wholly owned subsidiary and R&D operations in Beijing, China. More information on CASI is available at www.casipharmaceuticals.com and in CASI’s filings with the U.S. Securities and Exchange Commission.

CASI’s China rights to EVOMELA^® (melphalan) for Injection, MARQIBO^® (vinCRIStine sulfate LIPOSOME injection) and ZEVALIN^® (ibritumomab tiuxetan) were previously licensed from its partner Spectrum Pharmaceuticals, Inc. Based on the U.S. FDA’s approval of these three licensed products, CASI is pursuing the Import Drug registration path for approval in China.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including: that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the volatility in the market price of our common stock; risks relating to interests of our largest stockholders that differ from our other stockholders; the risk of substantial dilution of existing stockholders in future stock issuances, the difficulty of executing our business strategy in China; our inability to predict when or if our product candidates will be approved for marketing by the China Food and Drug Administration authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; risks associated with our product candidates; risks associated with any early-stage products under development; the risk that results in preclinical and early clinical models are not necessarily indicative of later clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks). Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

EVOMELA^®, MARQIBO^® and ZEVALIN^® are proprietary to Spectrum Pharmaceuticals, Inc. and its affiliates.

$AMWD To Acquire Cabinet Manufacturer RSI Home Products

Accretive Acquisition Adds Highly Profitable Kitchen and Bath Cabinetry and Home Storage Brands to American Woodmark’s Growing Portfolio

WINCHESTER, Va., Dec. 1, 2017 — American Woodmark Corporation (NASDAQ: AMWD) (“American Woodmark”) today announced that it has entered into a definitive agreement and plan of merger with RSI Home Products, Inc. (“RSI”), a leading manufacturer of kitchen and bath cabinetry and home storage products.  Under the terms of the agreement, the implied enterprise value for RSI is approximately $1.075 billion, including $140 million in American Woodmark common stock to be issued to RSI shareholders (based on the most recent 5 trading day average closing price), approximately $346 million in net cash to be paid to RSI shareholders and approximately $589 million of RSI debt to be assumed by American Woodmark.  The cash portion of the consideration is subject to customary working capital adjustments.

Founded in 1989 by Ron Simon with a vision of creating exceptional value for customers by providing high quality products at affordable prices not otherwise available in the industry, RSI has grown to one of the largest in-stock and value-based cabinet makers in North America providing kitchen, bathroom, home and garage organization cabinetry, counter tops and accessories with over 100 styles and finishes to home centers, builders, dealers and remodeling contractors.  RSI expects to generate net income of over $40 million and adjusted EBITDA of over $120 million on approximately $560 million of revenue for its fiscal year ending December 31, 2017, representing an adjusted EBITDA margin of over 21%.

The acquisition is expected to be immediately accretive to American Woodmark’s profit margins and earnings per share (“EPS”), excluding transaction costs and before giving effect to anticipated synergies.  Although there can be no assurance, the transaction is expected to close in American Woodmark’s quarter that ends January 31, 2018, subject to antitrust regulatory review and approvals and other customary closing conditions.  The transaction does not require approval of American Woodmark shareholders and has already received approval from the RSI shareholders.

“RSI has built a tremendous reputation and position in our industry by delivering quality products at a compelling value position, and we are excited to welcome them to the American Woodmark family,” said Cary Dunston, American Woodmark’s Chairman and CEO.  “The acquisition of RSI will further enhance American Woodmark by creating a broader product and brand portfolio that is well-positioned to fully leverage our industry-leading service platform across all channels and to drive improved profitability and long-term value for shareholders.  RSI’s strong culture of continuous improvement with a relentless focus on innovation and reengineering throughout their operational and business practices complements our existing capabilities.  Most importantly, American Woodmark and RSI share a similar culture that rests soundly on a foundation of extraordinary employees and creating value through people.”

Alex Calabrese, RSI’s Chairman and CEO commented, “This is an exciting day for RSI and reflects the hard work and dedication of everyone involved in our proud history and success over the past 28 years, most specifically, our dedicated associates as well as our valued customers and suppliers.  We have great respect for American Woodmark, and are honored to be joining forces with a company that shares our culture, values and vision.  This shared foundation makes the two companies an ideal fit.   RSI looks forward to continuing its growth and delivering the highest value and best services to its customers.”

“We couldn’t be more excited and optimistic about the future potential for RSI and its loyal employee associates,” said Ron Simon, RSI’s Founder and current director.  “This merger creates a company that will be a stronger competitor in the kitchen and bath industry than RSI could be on its own.  The fact that the two companies share the same culture in the way they value their associates and customers will go a long way to ensure great future success.  We believe RSI is the industry’s lowest cost manufacturer, and American Woodmark has unmatched logistics and service capabilities, as well as a very broad product line.  This combination enables American Woodmark to bring the greatest value by making higher quality products affordable to more consumers.”

Transaction Highlights
(Pro forma metrics represent unaudited financial information)

• The combined company will have approximately $1.6 billion in pro forma annual revenue along with a broader product portfolio that is well-positioned to deliver growth, improved profitability and shareholder value.
• Annual run-rate synergies are anticipated to be $30-40 million, phased in over 3 years, to be achieved through identified opportunities in sales and marketing, purchasing and manufacturing efficiencies through the sharing of operational best practices.
• American Woodmark expects to fund the $346 million net cash payment and transaction fees and expenses with cash on hand and committed financing from Wells Fargo Bank, National Association. American Woodmark also expects to enter into a new $100 million revolving credit facility with Wells Fargo Bank, National Association to replace its existing revolver and, if necessary, may draw on such facility for any remaining cash payments for the transaction.
• Prior to the closing of the transaction, RSI intends to conduct a consent solicitation with respect to its 6 ¹/₂% Senior Secured Second Lien Notes 2023 (the “RSI Notes”) in order to amend the related indenture so that the change of control provisions contained therein will not apply to the transaction. In addition, American Woodmark expects to explore options to refinance the RSI Notes either in connection with or after the closing of the transaction.
• Immediately following the closing of the transaction, RSI shareholders will own approximately 8% of American Woodmark shares outstanding. These shares will be subject to a six-month lock up period.
• American Woodmark is suspending its share repurchase program in conjunction with the transaction.
• The combined company will be managed by American Woodmark’s management team (led by Chairman and CEO Cary Dunston).
• RSI will operate as a subsidiary of American Woodmark following the transaction with its existing brands, channel strategy and operational philosophy remaining.

The Company will host a conference call today with investors, December 1, 2017 at 11:00 EST.  A presentation, which will accompany the call, will be available at www.americanwoodmark.com and will remain available after the call.

Advisors:

Robert W. Baird & Co. Incorporated is serving as financial advisor and McGuireWoods LLP is serving as legal counsel to American Woodmark.  Intrepid Investment Bankers LLC is serving as financial advisor and O’Melveny & Myers LLP is serving as legal counsel to RSI.

About RSI Home Products, Inc.:

Since RSI Home Products, Inc. was founded in 1989 it has been a customer-focused, quality-driven manufacturer of bath, kitchen and home organization products throughout the U.S. and Canada.  The company has outpaced its competition and continues to offer high-quality, low-cost, value-rich products.  RSI Home Products employs more than 4,200 people and has manufacturing and distribution facilities in California, North Carolina, Texas, and Mexico. For more information, visit www.rsihomeproducts.com.

About American Woodmark Corporation:

American Woodmark Corporation manufactures and distributes kitchen cabinets and vanities for the remodeling and new home construction markets.  Its products are sold on a national basis directly to home centers, major builders and through a network of independent distributors.  The Company presently operates nine manufacturing facilities and seven service centers across the country. For more information, visit www.americanwoodmark.com.

Forward Looking Statements

This communication contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements as to the anticipated timing of completion of the proposed transaction, expected cost synergies, future financial and operating results, and other expected effects of the proposed transaction.  These forward-looking statements may be identified by the use of words such as “anticipate,” “estimate,” “forecast,” “expect,” “believe,” “should,” “could,” “would,” “plan,” “may,” ” intend,” “prospect,” “goal,” “will,” “predict,” or “potential” or other similar words or variations thereof.  These statements are based on the current beliefs and expectations of the management of American Woodmark and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially from those expressed herein.  These risks and uncertainties include, but are not limited to, the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement or a delay in the completion of the proposed transaction, a failure by either or both parties to satisfy conditions to closing, a failure to obtain any required regulatory or third-party approvals, including any required antitrust approvals, risks associated with the financing of the transaction, the effect of the announcement of the proposed transaction on the ability of American Woodmark and RSI to retain customers, maintain relationships with their suppliers and hire and retain key personnel, American Woodmark’s ability to successfully integrate RSI into its business and operations, and the risk that the economic benefits, costs savings and other synergies anticipated by American Woodmark are not fully realized or take longer to realize than expected.  Additional risks and uncertainties that could impact American Woodmark’s future operations and financial results are contained in American Woodmark’s filings with the Securities and Exchange Commission (“SEC”), including in its Annual Report on Form 10-K for the year ended April 30, 2017 under the heading “Risk Factors” and its most recent Quarterly Report on Form 10-Q for the period ended July 31, 2017 under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Forward Looking Statements.”  These reports, as well as the other documents filed by American Woodmark with the SEC, are available free of charge at the SEC’s website at www.sec.gov.

Non-GAAP Reconciliation

The following information provides reconciliations of non-GAAP financial measures from operations, which are presented in the accompanying presentation, to the most comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”).  Each company has provided non-GAAP financial measures, which are not calculated or presented in accordance with GAAP, as information supplemental and in addition to the financial measures presented in the accompanying presentation that are calculated and presented in accordance with GAAP. Such non-GAAP financial measures should not be considered superior to, as a substitute for, or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented in the presentation.  The non-GAAP financial measures in the accompanying presentation may differ from similar measures used by other companies.  The following tables reconcile the non-GAAP measure of Earnings Before Interest, Taxes, Depreciation and Amortization, as adjusted (“Adjusted EBITDA”) referred to in this presentation to the most directly comparable GAAP measure reflected in each company’s financial statements.

_______________________

Note: Adjusted EBITDA defined as operating income plus depreciation and amortization and impact of certain non-recurring / non-cash items not considered to be part of normal operations.

Note:  the estimated financial numbers for RSI and American Woodmark provided above represent estimates by RSI’s management and American Woodmark’s management, respectively, as of the date of this release only and (i) are based upon a number of assumptions and estimates that are inherently subject to business, economic and competitive uncertainties and contingencies, many of which are beyond our control, (ii) are based upon certain specific assumptions with respect to future business decisions, some of which will change, and (iii) are necessarily speculative in nature.   Some or all of the assumptions and estimates utilized may not materialize or may vary significantly from actual results.   As a result, investors are urged to put the estimated numbers provided in context and not to place undue reliance on them.

$FCEL and Toyota $TM Announce Renewable Transportation Fuel Project

• FuelCell Energy to install fuel cell power plant at Port of Long Beach, California to generate renewable hydrogen and power
• Toyota to purchase renewable hydrogen for fuel cell vehicle refueling
• Power generated by the fuel cells will be sold to the grid under State of California Bioenergy Market Adjustment Tariff (BioMAT) program

DANBURY, Conn., Nov. 30, 2017 — FuelCell Energy, Inc.  (Nasdaq:FCEL), a global leader in delivering clean, innovative and affordable fuel cell solutions for the supply, recovery and storage of energy, today announced the execution of a hydrogen and power off-take agreement with Toyota, outlining an innovative collaboration  in which Toyota will purchase renewable hydrogen for vehicle fueling generated on-site from a multi-megawatt SureSource^TM fuel cell  power plant located at the Port of Long Beach in California.  FuelCell Energy will install and operate a fuel cell power plant that will be configured for hydrogen production to generate and supply 100 percent renewable hydrogen for Toyota’s fuel cell electric vehicles (FCEV’s) and its heavy duty fuel cell Class 8 proof of concept truck.  The fuel cell plant will simultaneously generate renewable power to be supplied to the grid under the California Bioenergy Market Adjustment Tariff (BioMAT) program.  This fuel cell solution meets Toyota’s fueling needs affordably and sustainably, while supporting the advancement of California’s hydrogen fueling infrastructure and adhering to the state’s mandate for utilizing low-carbon and renewable sources.

“Fueling our Proof of concept Semi-Truck, as well as our Mirai fuel cell electric vehicles with 100 percent renewable hydrogen from this stationary fuel cell system is a major accomplishment, and a key step in building a sustainable hydrogen ecosystem to help power Port operations,” said Doug Murtha, Group Vice President – Strategic Planning, Toyota. “Toyota is a company dedicated to advancing sustainability, and this project supports our ongoing efforts to both eliminate carbon emissions and accelerate the development and adoption of emission-free fuel cell electric vehicles.”

“This is an innovative and replicable global model for building an affordable hydrogen infrastructure to generate renewable transportation fuel that facilitates the wider adoption of fuel cell electric cars, trucks and buses,” said Chip Bottone, Chief Executive Officer, FuelCell Energy, Inc. “We are pleased to provide Toyota with a flexible project structure that meets their needs both sustainably and economically.”

FuelCell Energy’s distributed hydrogen solution co-produces hydrogen and clean power from methane based fuels such as renewable biogas.  The methane is reformed to hydrogen using water and heat produced by the fuel cell, resulting in clean hydrogen production without water consumption.  In January 2016 the California Air Resources Board (CARB) certified a prospective pathway for hydrogen production with this technology fueled by biogas.  CARB’s team performed a complete Life Cycle Analysis (LCA) on the system and determined that it has a negative carbon intensity, as the power and hydrogen generation process is carbon-neutral due to the use of renewable biogas and the fuel cell waste heat is used to feed the internal reformation reactions.

The multi-megawatt SureSource Hydrogen^TM plant will be located at the Port of Long Beach, generating renewable hydrogen to fuel Toyota’s Mirai vehicles as they arrive at the Port and its heavy-duty fuel cell Class 8 proof of concept truck.

Fuel cells utilize an electro-chemical process to convert a fuel source into electricity and heat in a highly efficient process that emits virtually no pollutants as the fuel is not burned.  The combination of near-zero pollutants, modest land-use needs, and quiet operating nature of these stationary fuel cell power plants facilitates installation in urban locations where the power is used.  Customers benefit with operating cost reductions delivered in a manner that supports sustainability goals and enhances power reliability.

Cautionary Language 
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements with respect to Fuelcell’s expectations regarding energy cost savings, overall system efficiency, expectation regarding the amount of power generation and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of FuelCell and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and FuelCell undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although FuelCell believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements.  For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of FuelCell in general, see the risk disclosures in FuelCell’s filings with the Securities and Exchange Commission.

About FuelCell Energy
FuelCell Energy (NASDAQ:FCEL) delivers efficient, affordable and clean solutions for the supply, recovery and storage of energy.  We design, manufacture, undertake project development, install, operate and maintain megawatt-scale fuel cell systems, serving utilities, industrial and large municipal power users with solutions that include both utility-scale and on-site power generation, carbon capture, local hydrogen production for transportation and industry, and long duration energy storage.  With SureSource™ installations on three continents and millions of megawatt hours of ultra-clean power produced, FuelCell Energy is a global leader with environmentally responsible power solutions.  Visit us online at www.fuelcellenergy.com and follow us on Twitter.

SureSource, SureSource 1500, SureSource 3000, SureSource 4000, SureSource Recovery, SureSource Capture, SureSource Hydrogen, SureSource Storage, SureSource Service, SureSource Capital, FuelCell Energy, and FuelCell Energy logo are all trademarks of FuelCell Energy, Inc.

Contact:
FuelCell Energy, Inc.
Kurt Goddard, Vice President Investor Relations
203-830-7494
ir@fce.com

$AKAO to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2017 — Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that management will be hosting investor meetings at the Guggenheim Securities 5^th Annual Boston Healthcare Conference on Wednesday, December 13, 2017 at The InterContinental Boston Hotel in Boston, Massachusetts.

Investors attending the conference who are interested in meeting with Achaogen management should contact their Guggenheim Securities representative.

About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. The Food and Drug Administration has granted plazomicin Breakthrough Therapy designation for the treatment of bloodstream infections caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options. The Company’s second product candidate is C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination. Achaogen’s plazomicin program has been funded, and its C-Scape program is funded, in part with Federal funds from the Biomedical Advanced Research and Development Authority. Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections and additional disease areas. All product candidates, including plazomicin, are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.

Source: Achaogen, Inc. (NASDAQ:AKAO)

Investor and Media Contact
David Arrington
Vice President, Investor Relations and Corporate Communications
650.440.5856
darrington@achaogen.com

$CYTK Phase 1 Studies of CK-2127107 Highlights Tolerability, Pharmacodynamics

Next Generation Fast Skeletal Muscle Activator Appears Promising Compared to Tirasemtiv in Studies of Healthy Volunteers

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2017 — Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the publication of results from three double-blind, randomized, placebo-controlled Phase 1 clinical studies that evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of CK-2127107, an investigational next-generation fast skeletal muscle troponin activator (FSTA). The results showed that CK-2127107 increased the force generated by the tibialis anterior muscle versus placebo in response to nerve stimulation in a dose, plasma concentration, and frequency-dependent manner. Single doses of CK-2127107 were well-tolerated in healthy volunteers at doses up to 4000 mg. No serious adverse effects (SAEs) were reported and adverse effects (AEs) were all mild or moderate. Additionally, the results showed that CK-2127107 appeared more potent and produced a larger increase in force than tirasemtiv which was evaluated in a comparable study.¹ The publication, titled “CK-2127107 Amplifies Skeletal Muscle Response to Nerve Activation in Humans,” is published online in Muscle & Nerve.²

“These published results reinforce CK-2127107 as a promising drug candidate with potential advantages relative to tirasemtiv that may include tolerability and potency,” said Fady I. Malik, MD, PhD, Cytokinetics’ Executive Vice President of Research & Development. “We look forward to the results from four ongoing mid-stage clinical trials of CK-2127107 anticipated in 2018.”

CY 5011 was a single ascending dose crossover clinical trial that evaluated the safety, tolerability and pharmacokinetics of single doses of CK-2127107 in 35 healthy male participants. Participants received two ascending, active doses and one placebo dose, one in each of three treatment periods. CK-2127107 was well tolerated at all dose levels ranging from 30 mg to 4000 mg. A maximum tolerated dose was not achieved. All AEs were mild or moderate, and no clinically meaningful changes from baseline were observed in the neurological examination, walk test, laboratory values, vital signs, ECG parameters or pulse oximetry. Exposure to CK-2127107 increased approximately dose proportionally.

CY 5012 was a multiple ascending dose, parallel group clinical trial that evaluated the safety, tolerability and pharmacokinetics of CK-2127107 in male and female healthy volunteers. The clinical trial enrolled 59 young (aged 18-55) and elderly (aged 65-85) participants. Three cohorts enrolled young participants and two enrolled elderly participants; four cohorts received 300 mg or 500 mg for 10 days and one cohort received 500 mg for 17 days. CK-2127107 was generally well-tolerated at all doses administered, and all AEs were mild or moderate. No other clinically meaningful changes from baseline were observed in other laboratory values, neurological examination, vital signs, or ECG parameters, and there were no clinically meaningful differences in pharmacokinetics of CK-2127107 between young and elderly participants. Steady state was achieved in elderly participants dosed with 300 mg for 10 days and young participants taking 500 mg for 17 days.

CY 5013 was a single-dose, four-period crossover clinical trial of CK-2127107 in 16 healthy male participants that evaluated the change in the force-frequency profile of the tibialis anterior muscle during transcutaneous stimulation of the deep fibular nerve and its relationship to dose and plasma concentrations of CK-2127107. Participants received placebo, 300 mg, 1000 mg and 3000 mg single doses in random order administered one week apart. Single doses were well-tolerated and all AEs were mild or moderate. CK-2127107 increased the response of the tibialis anterior muscle to neuronal input as dose and plasma concentration increased. The overall largest increase from baseline in peak force, compared to placebo, was 58.7 (10.2)% (least-squares mean [SE]) occurring at a stimulation frequency of 10 Hz. For comparison, the largest response tirasemtiv produced in a comparable study was a 24.5 (3.1)% increase in peak force at 10 Hz.¹ The effect of CK-2127107 on the force-frequency relationship was also related to the stimulation frequency, being greatest at approximately the rate that motor units typically discharge during daily physical activity.

These results suggest that by directly increasing skeletal muscle force production, with maximal effects in the middle of the 5 to 15 Hz range where most normal daily human muscle activity occurs^3,4, CK-2127107 may have an effect on physical performance in patients with neuromuscular and non-neuromuscular diseases in which weakness and fatigue are the result of reduced skeletal muscle force production. Furthermore, the results show that compared to the first-generation FSTA tirasemtiv, CK-2127107 may be more potent and produce larger increases in force.

About CK-2127107

CK-2127107 is an investigational next-generation FSTA arising from Cytokinetics’ skeletal muscle contractility program. CK-2127107 was derived from a different chemical structural class and was designed to have certain advantages relative to tirasemtiv. CK-2127107 appears to be more potent than tirasemtiv in preclinical models and in humans and appears better tolerated compared to tirasemtiv in comparable Phase 1 studies. CK-2127107 has demonstrated pharmacological activity that diseases associated with muscle weakness and fatigue. CK-2127107 has been the subject of five completed Phase 1 clinical trials in healthy volunteers, which evaluated the safety, tolerability, bioavailability, pharmacokinetics and pharmacodynamics of the drug candidate. CK-2127107 is the subject of an ongoing clinical development program in neuromuscular and non-neuromuscular diseases and conditions associated with muscle dysfunction and weakness, including three Phase 2 trials currently underway in patients with each of spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), or chronic obstructive pulmonary disease (COPD), as well as a Phase 1b trial in elderly subjects with limited mobility.

About Cytokinetics and Astellas Collaboration

Cytokinetics and Astellas collaborate on the research, development, and commercialization of skeletal muscle activators. The primary objective of the collaboration is to advance novel therapies for diseases and medical conditions associated with muscle impairment and weakness. Cytokinetics has licensed to Astellas exclusive rights to develop and commercialize CK-2127107 and other FSTAs in non-neuromuscular indications and certain neuromuscular indications (including SMA and ALS) and other novel mechanism skeletal muscle activators in all indications, subject to certain Cytokinetics’ development and commercialization rights; Cytokinetics may co-promote and conduct certain commercial activities in North America and Europe under agreed scenarios.

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics is collaborating with Astellas Pharma Inc. (“Astellas”) to develop CK-2127107, a next-generation FSTA. CK-2127107 has been granted orphan drug designation by the FDA for the potential treatment of SMA. CK-2127107 is the subject of three ongoing Phase 2 clinical trials enrolling patients with spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. Astellas is also conducting a Phase 1b clinical trial of CK-2127107 in elderly adults with limited mobility. Astellas holds an exclusive worldwide license to develop and commercialize CK-2127107. Cytokinetics is collaborating with Amgen Inc. (“Amgen”) to develop omecamtiv mecarbil, a novel cardiac muscle activator. Omecamtiv mecarbil is the subject of GALACTIC-HF, an international Phase 3 clinical trial in patients with heart failure. Amgen holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and certain other countries. Licenses held by Amgen and Astellas are subject to Cytokinetics’ specified co-development and co-commercialization rights. For additional information about Cytokinetics, visit www.cytokinetics.com.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities, including our continuing review and assessment related to the results from VITALITY-ALS, our evaluation, in consultation with the FDA and other regulatory authorities of future development plans for tirasemtiv and the process and timing of anticipated future development of tirasemtiv; the design, results, significance and utility of preclinical study results; and the properties and potential benefits of CK-2127107 and Cytokinetics’ other drug candidates.  Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trial results, patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy, the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ or its partners’ ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Astellas’ decisions with respect to the design, initiation, conduct, timing and continuation of development activities for CK-2127107; Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales under Cytokinetics’ collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.

References

1. Hansen R, Saikali KG, Chou W, Russell AJ, Chen MM, Vijayakumar V, Stoltz RR, Baudry S,  Enoka RM, Morgans DJ, Wolff AA, Malik FI. Tirasemtiv amplifies skeletal muscle response to nerve activation in humans. Muscle & Nerve. 2014 Dec;50(6):925-31.
2. Andrews JA, Miller TM, Vijayakumar V, Stoltz R, James JK, Meng L, Wolff AA, Malik FI. CK-2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle & Nerve. 2017 Nov 18.
3. Person RS, Kudina LP. Discharge frequency and discharge pattern of human motor units during voluntary contraction of muscle. Electroencephalography and clinical neurophysiology. 1972;32(5):471-483.
4. Tanji J, Kato M. Firing rate of individual motor units in voluntary contraction of abductor digiti minimi muscle in man. Experimental neurology. 1973;40(3):771-783.

Contact:
Cytokinetics
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(415) 290-7757

$YGYI Subsidiary, CLR Roasters, Purchases $7.5 Million of Green Coffee Contracts for 2018

$IMMR Appointment of Board Chair, Carl Schlachte, as Interim CEO

SAN JOSE, Calif.

Immersion Corp. (Nasdaq: IMMR), the leading developer and licensor of touch feedback technology, today announced that at the request of the Board of Directors, Vic Viegas has agreed to resign as Chief Executive Officer and as a director.

Carl Schlachte, currently Chairman of the Board, has been unanimously elected by the Board as Interim CEO. Mr. Schlachte joined the Immersion Board in 2011 and was elected as Chairman in 2012. He currently serves as Chairman and CEO of Ventiva, Inc., which designs and develops thermal management technologies for consumer applications in mobile computing, power electronics and LED lighting. He will continue to serve as Chairman of the Board of Immersion during his tenure as Interim CEO.

“After a thorough review of our business and strategy, the Board has decided to pursue new leadership for the company. We are commencing a search for a permanent CEO, and until the completion of this process, I am honored that the Board has put its trust in me to serve as Interim CEO,” said Mr. Schlachte. “On behalf of the Board, I want to thank Vic for his years of dedicated service to Immersion. We wish him the very best.”

“Immersion’s recently announced licensing agreements continue to demonstrate that the technology and IP developed by our employees have significant value around the world,” Mr. Schlachte said. “As a long-time Board member, I am a deep believer in the value of our haptic technology solutions, as well as in our innovative culture and strong intellectual property portfolio. I am excited about the opportunities in front of Immersion.”

About Immersion

Immersion is the leading innovator of touch feedback technology, also known as haptics. The company provides technology solutions for creating immersive and realistic experiences that enhance digital interactions by engaging users’ sense of touch. With more than 2,600 issued or pending patents, Immersion’s technology has been adopted in more than 3 billion digital devices, and provides haptics in mobile, automotive, advertising, gaming, medical and consumer electronics products. Immersion is headquartered in San Jose, California with offices worldwide. Learn more at www.immersion.com.

Forward Looking Statements

This press release contains “forward-looking statements” that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause the results of Immersion Corporation and its consolidated subsidiaries to differ materially from those expressed or implied by such forward-looking statements. All statements, other than the statements of historical fact, are statements that may be deemed forward-looking statements, including, but not limited to, statements regarding the company’s leadership transition, the benefits of Immersion’s technology and its business strategy.

Immersion’s actual results might differ materially from those stated or implied by such forward-looking statements due to risks and uncertainties associated with Immersion’s business, which include, but are not limited to: unanticipated difficulties and challenges encountered in product development efforts by Immersion and its licensees; adverse outcomes in any future intellectual property-related litigation and the costs related thereto; the effects of the current macroeconomic climate; delay in or failure to achieve adoption of or commercial demand for Immersion’s products or third party products incorporating Immersion’s technologies; and a delay in or failure to achieve the acceptance of touch feedback as a critical user experience. Many of these risks and uncertainties are beyond the control of Immersion.

For a more detailed discussion of these factors, and other factors that could cause actual results to vary materially, interested parties should review the risk factors listed in Immersion’s most current Form 10-K, and Form 10-Q, both of which are on file with the U.S. Securities and Exchange Commission. The forward-looking statements in this press release reflect Immersion’s beliefs and predictions as of the date of this release. Immersion disclaims any obligation to update these forward-looking statements as a result of financial, business, or any other developments occurring after the date of this release.

Immersion and the Immersion logo are trademarks of Immersion Corporation in the United States and other countries. All other trademarks are the property of their respective owners.

(IMMR – C)

$MYSZ Will Participate in the International CES Tradeshow

$ESND to Attend 2017 KeyBanc Capital Markets Consumer Conference

DEERFIELD, Ill., Nov. 29, 2017 — Essendant Inc. (NASDAQ:ESND), a leading national wholesale distributor of workplace essentials, today announced that Ric Phillips, president and chief executive officer, and Janet Zelenka, senior vice president and chief financial officer, will host investor meetings at the 2017 KeyBanc Capital Markets Consumer Conference at the InterContinental New York Barclay in New York on Wednesday, December 6, 2017.

An updated investor presentation will be available on the date of the conference on the Investors section of Essendant’s website, on the Presentations page at investors.essendant.com.

About Essendant
Essendant Inc. is a leading supplier of workplace essentials, with 2016 net sales of $5.4 billion. The company stocks a broad assortment of over 190,000 items, including technology products, traditional office products, janitorial and breakroom supplies, office furniture, industrial supplies, and automotive aftermarket tools. The Company’s network of 70 distribution centers enables the Company to ship most products overnight to more than ninety percent of the U.S. For more information, visit www.essendant.com.

Essendant’s common stock trades on the NASDAQ Global Select Market under the symbol ESND.

For Investor Inquiries:
investorrelations@essendant.com
847.627.2900

$FTR to Participate in UBS 45th Annual GMCC

NORWALK, Conn.

Frontier Communications Corporation announced today that its Executive Vice President and Chief Financial Officer, Perley McBride, is scheduled to present at the UBS 45^th Annual Global Media and Communications Conference in New York, N.Y. on Tuesday, December 5, 2017, at 9:30 A.M. Eastern Time.

A live webcast will be available at Frontier’s Investor Relations website under “Webcasts and Presentations.”

About Frontier Communications

Frontier Communications Corporation (NASDAQ:FTR) is a leader in providing communications services to urban, suburban, and rural communities in 29 states. Frontier offers a variety of services to residential customers over its fiber-optic and copper networks, including video, high-speed Internet, advanced voice, and Frontier Secure^® digital protection solutions. Frontier Business offers communications solutions to small, medium, and enterprise businesses. More information about Frontier is available at www.frontier.com.

$CAPR Announces FDA Clearance of IND Application for CAP-1002

Potential Registration Trial in Duchenne Muscular Dystrophy on Track to Initiate in First Quarter of 2018 Company to Host Conference Call and Webcast at 4:30 p.m. ET Today

LOS ANGELES, Nov. 29, 2017 — Capricor Therapeutics (NASDAQ: CAPR) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a new clinical trial of CAP-1002, its lead investigational therapy, in boys and young men in advanced stages of Duchenne muscular dystrophy, a fatal genetic disorder for which there are limited treatment options.

This randomized, double-blind, placebo-controlled clinical trial will be called the HOPE-2 Trial and is designed to evaluate the safety and efficacy of intravenous, repeat doses of CAP-1002 in boys and young men whose ability to walk has been seriously impaired by the loss of muscle function that occurs as Duchenne muscular dystrophy progresses. The primary efficacy endpoint will be the relative change in the mid-level dimension of the Performance of the Upper Limb test from baseline to Month 12. The HOPE-2 Trial is expected to enroll approximately 84 patients and be conducted at 10-12 U.S. sites.

Capricor believes that if the primary endpoint is reached, the HOPE-2 Trial could serve as a registration trial, meaning that its results could support the submission of a Biologics License Application (BLA) to obtain marketing approval of CAP-1002. Capricor expects to initiate the HOPE-2 Trial in the first quarter of 2018.

Capricor plans to apply for the Regenerative Medicine Advanced Therapy (RMAT) Designation for CAP-1002 based on updated guidance recently issued by the FDA. If granted, the RMAT Designation would be expected to facilitate CAP-1002’s path to potential registration.

The national principal investigator for the HOPE-2 trial will be Craig M. McDonald, M.D., a distinguished thought leader in the clinical management of neuromuscular diseases, including muscular dystrophies, and the development of novel outcome measures for Duchenne muscular dystrophy clinical trials.

“The FDA’s clearance of this IND upon its initial submission is a significant step forward in our development of CAP-1002,” said Linda Marbán, Ph.D., president and chief executive officer. “While there are many clinical initiatives in Duchenne muscular dystrophy, this is one of the very few to focus on non-ambulant patients. These boys and young men are looking to maintain what function they have in their arms and hands and, based on our previous study, we think CAP-1002 may be able to do exactly that.”

Capricor previously reported significant and sustained improvements in cardiac structure and function, as well as skeletal muscle function, following a single dose of intracoronary CAP-1002. The HOPE-2 Trial will test the potential benefit of CAP-1002 as a repeated therapy delivered intravenously, with the goal of providing long-term benefit in a format that is compatible with repeat dosing over time. Support for intravenous infusion, a common mode of drug delivery, is provided by studies which have shown therapeutic benefit in an animal model of Duchenne muscular dystrophy.

Capricor will hold a conference call and slide presentation at 4:30 p.m. ET today to discuss this development. To join: please dial 1-866-652-5200 (domestic) or 1-412-317-6060 (international). Access to the webcast and a replay of the call may be found at http://capricor.com/news/events/.

The HOPE trial was funded in part by the California Institute for Regenerative Medicine.

About Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is a devastating genetic disorder that causes muscle degeneration and leads to death, generally before the age of 30, most commonly from heart failure. It occurs in one in every 3,600 live male births across all races, cultures and countries. Duchenne muscular dystrophy afflicts approximately 200,000 boys and young men around the world. Treatment options are limited, and there is no cure.

About CAP-1002

CAP-1002 consists of allogeneic cardiosphere-derived cells, or CDCs, a unique population of cells that contains cardiac progenitor cells. CAP-1002 has been shown to exert potent immunomodulatory activity and stimulate cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. For more information, visit www.capricor.com.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings, and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the Securities and Exchange Commission on March 16, 2017, in its Registration Statement on Form S-3, as filed with the Securities and Exchange Commission on September 28, 2015, together with the prospectus included therein and prospectus supplements thereto, and in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, as filed with the Securities and Exchange Commission on November 14, 2017. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

CAP-1002 is an Investigational New Drug and is not approved for any indications. Capricor’s exosomes technology, including CAP-2003, has not yet been approved for clinical investigation.

For more information, please contact:

AJ Bergmann, Vice President of Finance
+1-310-358-3200
abergmann@capricor.com

$SLM Employee Everet Zicarelli Named 2017 Emerging Leader

NEWARK, Del.

Everet Zicarelli, a member of Sallie Mae’s internal audit team, was honored as a 2017 Emerging Leader by Internal Auditor magazine, a publication produced by the Institute of Internal Auditors (IIA). The publication recognizes up-and-coming internal audit practitioners who are making a difference within their companies, willing to take on new roles and challenges, and mentor younger professionals in the field. Zicarelli was one of only 15 professionals across the globe, all under 30 years old, to be recognized.

“Within Sallie Mae’s internal audit department, we are committed to ensuring our business practices are constantly reviewed and improved to ensure the highest standards for our customers,” said Dan VanSciver, senior vice president and chief audit officer, Sallie Mae. “We also promote continued professional development among our employees, so it’s particularly gratifying to see Everet recognized for his great work.”

Zicarelli joined the internal audit department at Sallie Mae in May 2015 and was promoted to senior internal auditor in March 2016. He is a leader within the company’s on-campus internship recruiting program and is the designated mentor for all internal audit interns. He recently began volunteering at the University of Delaware’s Center for Economic Education and Entrepreneurship Keys to Financial Success program, which prepares K-12 educators and students in economics, personal finance, and entrepreneurship.

Zicarelli is a graduate of the University of Delaware. He received his Certified Internal Auditor (CIA) certification from the Institute of Internal Auditors and was a recipient of their William S. Smith CIA – Certificate of Honors Award for his performance on the CIA examination. He is also a Certified Public Accountant (CPA) licensed in the state of Delaware. In addition to the recognition from the IIA, he recently received a Quarterly Employee Award of Excellence from Sallie Mae.

For more information about saving, planning, and paying for college, visit SallieMae.com.

Sallie Mae (Nasdaq: SLM) is the nation’s saving, planning, and paying for college company. Whether college is a long way off or just around the corner, Sallie Mae offers products that promote responsible personal finance, including private education loans, Upromise rewards, scholarship search, college financial planning tools, and online retail banking. Learn more at SallieMae.com. Commonly known as Sallie Mae, SLM Corporation and its subsidiaries are not sponsored by or agencies of the United States of America.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171129006113/en/

$LBTYA to Present at the UBS 45th Annual Global Media and Communications Conference

DENVER, Colorado

Liberty Global plc (“Liberty Global”) (NASDAQ: LBTYA, LBTYB, LBTYK, LILA and LILAK) will be presenting at the UBS 45th Annual Global Media and Communications Conference on Wednesday, December 6, 2017 at 12:00 p.m. EST at the Grand Hyatt New York in New York City. Liberty Global CEO Mike Fries will be presenting. Liberty Global may make observations concerning its historical operating performance and outlook. The presentation will be webcast live at www.libertyglobal.com. We intend to archive the webcast under the investor relations section of our website for approximately 30 days.

About Liberty Global

Liberty Global is the world’s largest international TV and broadband company, with operations in more than 30 countries across Europe, Latin America and the Caribbean. We invest in the infrastructure that empowers our customers to make the most of the digital revolution. Our scale and commitment to innovation enable us to develop market-leading products delivered through next-generation networks that connect our over 24 million customers who subscribe to over 50 million television, broadband internet and telephony services. We also serve over 10 million mobile subscribers and offer WiFi service across 10 million access points.

Liberty Global’s businesses are comprised of two stocks: the Liberty Global Group (NASDAQ: LBTYA, LBTYB and LBTYK) for our European operations, and the LiLAC Group (NASDAQ: LILA and LILAK, OTC Link: LILAB), which consists of our operations in Latin America and the Caribbean.

The Liberty Global Group operates in 12 European countries under the consumer brands Virgin Media, Unitymedia, Telenet and UPC. The Liberty Global Group also owns 50% of VodafoneZiggo, a Dutch joint venture, which has 4 million customers, 10 million fixed-line subscribers and 5 million mobile subscribers. The LiLAC Group operates in over 20 countries in Latin America and the Caribbean under the consumer brands VTR, Flow, Liberty, Más Móvil and BTC. In addition, the LiLAC Group operates a sub-sea fiber network throughout the region connecting over 40 markets.

For more information, please visit www.libertyglobal.com.

Liberty Global
Investor Relations:
Oskar Nooij, +1 303 220 4218
Christian Fangmann, +49 221 8462 5151
John Rea, +1 303 220 4238
or
Corporate Communications:
Matt Beake, +44 20 8483 6428
Julia Hart, +31 20 778 3345

$AMSC Announces $8 Million in D-VAR® System Orders

D-VAR Systems to Support Renewable Connectivity Applications in the U.K. and Industrial Power Quality in the U.S.

DEVENS, Mass., Nov. 29, 2017 — AMSC (NASDAQ:AMSC), a global energy solutions provider serving wind and power grid industry leaders, today announced four new D-VAR® STATCOM system orders valued at over $8 million. Two of the orders serve the renewable energy sector and are expected to be used for connection of wind power plants to the electric grid in the United Kingdom, as well as to provide voltage regulation by responding dynamically to varying load conditions. Two of the orders serve the industrial power quality sector in the United States. Revenue from these four D-VAR® orders is expected to be recognized in fiscal year 2017.

AMSC’s D-VAR interconnection and reactive power compensation solutions are designed to ensure high network performance and stability. The system is a powerful, cost-effective way to provide continuous voltage regulation, improve voltage stability, meet interconnection requirements, and dynamically provide grid support where it is needed.

“We believe that these D-VAR orders represent continued progress toward our objective to grow our Grid revenues year over year,” said Daniel P. McGahn, President and CEO, AMSC. “I am pleased that these orders for industrial applications in the U.S. include two repeat customers in the power quality market.”

Customers utilize AMSC’s D-VAR solutions to provide dynamic voltage control, power factor correction, and post-contingency reactive compensation to stabilize the power grid and prevent undesirable events such as voltage collapse. The D-VAR system is designed to be able to detect and instantaneously compensate for voltage disturbances by dynamically injecting leading or lagging reactive power into the power grid. These solutions are also designed to augment the overall performance of wind farms and to enable developers to meet grid interconnection requirements.

D-VAR reactive compensation systems are classified as Static Compensators, or “STATCOMs,” a member of the FACTS (Flexible AC-Transmission System) family of power electronic solutions for alternating current (AC) power grids.

About AMSC (NASDAQ: AMSC)
AMSC generates the ideas, technologies and solutions that meet the world’s demand for smarter, cleaner … better energy™. Through its Windtec™ Solutions, AMSC provides wind turbine electronic controls and systems, designs and engineering services that reduce the cost of wind energy. Through its Gridtec™ Solutions, AMSC provides the engineering planning services and advanced grid systems that optimize network reliability, efficiency, and performance. AMSC’s solutions are now powering gigawatts of renewable energy globally and are enhancing the performance and reliability of power networks in more than a dozen countries. Founded in 1987, AMSC is headquartered near Boston, Massachusetts with operations in Asia, Australia, Europe, and North America. For more information, please visit www.amsc.com.

AMSC, Windtec, Gridtec, D-VAR, and Smarter, Cleaner … Better Energy are trademarks or registered trademarks of American Superconductor Corporation. All other brand names, product names, trademarks, or service marks belong to their respective holders.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such statements include, but are not limited to, statements about our expectations regarding intended uses of the D-VAR systems; the timing of revenue recognition for the D-VAR systems ordered; and functionality and performance of D-VAR systems; our belief that these D-VAR orders represent continued progress toward achieving our objective to grow our Grid revenues year over year; and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions. Such forward-looking statements represent management’s current expectations and are inherently uncertain. There are a number of important factors that could materially impact the value of our common stock or cause actual results to differ materially from those indicated by such forward-looking statements. These important factors include, but are not limited to: We have a history of operating losses and negative operating cash flows, which may continue in the future and require us additional financing in the future; Our operating results may fluctuate significantly from quarter to quarter and may fall below expectations in any particular fiscal quarter; Our financial condition may have an adverse effect on our customer and supplier relationships; Our success is dependent upon attracting and retaining qualified personnel and our inability to do so could significantly damage our business and prospects; Failure to successfully execute any move of our Devens, Massachusetts manufacturing facility or achieve expected savings following any such move; We rely upon third-party suppliers for the components and sub-assemblies of many of our Wind and Grid products, making us vulnerable to supply shortages and price fluctuations; Our products face intense competition; Many of our revenue opportunities are dependent upon subcontractors and other business collaborators; We may not realize all of the sales expected from our backlog of orders and contracts; We have operations in and depend on sales in emerging markets, and global conditions could negatively affect our operating results or limit our ability to expand our operations outside of these countries; We face risks related to our intellectual property; We face risks related to our legal proceedings; and the important factors discussed under the caption “Risk Factors” in Part 1. Item 1A of our Form 10-K for the fiscal year ended March 31, 2017, and our other reports filed with the SEC. These important factors, among others, could cause actual results to differ materially from those indicated by forward-looking statements made herein and presented elsewhere by management from time to time. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Relations Contact:
Brion D. Tanous
CleanTech IR, Inc.
Phone: 424-634-8592
Email: Brion.Tanous@amsc.com

Public Relations Contact:
Nicol Golez
Phone: 978-399-8344
Email: Nicol.Golez@amsc.com

$OESX Expects $1.4M in Revenue from New U.S. Government Retrofit Awards

Annual Energy Savings of Approximately 70% Should Enable Full Recoupment of Installation Costs in a Few Years

MANITOWOC, Wis., Nov. 28, 2017 — Orion Energy Systems, Inc. (NASDAQ:OESX) (Orion Lighting), a leading designer and U.S. manufacturer of high-performance, energy-efficient LED lighting products, announced today the receipt of award notifications to retrofit three U.S. Government facilities with Orion’s LED lighting systems. Orion expects to record at least $1.4 million in revenue from these awards over the balance of its fiscal 2018 year ending March 31, 2018. The bulk of the revenue will be product sales, along with installation services and some engineering and professional services.

Orion is replacing legacy lighting systems at the government facilities with its energy-efficient LED lighting platforms and controls, in support of the customer’s environmental and energy efficiency goals. The customer expects to reduce its annual lighting energy usage by approximately 70%, providing savings that should allow the full recoupment of all project costs in just a few years. The awards follow several projects completed for this government entity over the past few years. Orion anticipates additional retrofit opportunities from this customer in future periods.

Orion CEO, Mike Altschaefl, commented, “We are proud to serve our Country and build upon past work with this valued, long-time U.S. government customer. These awards confirm the strength of our product platform, design, features and value proposition – factors that are resonating with a growing base of new and existing customers.

“Importantly, they also confirm our customer’s confidence in Orion, our commitment to customer satisfaction, and the strong working relationship we have built over several years. Our activity in the government sector continues to be strong, and we are eager to bid on future projects for this customer.”

About Orion Energy Systems
Orion is a leading designer and producer of energy efficient lighting and retrofit lighting solutions for commercial and industrial buildings. Orion manufactures and markets connected lighting systems encompassing LED solid-state lighting and smart controls. Orion systems incorporate patented design elements that deliver significant energy, efficiency, optical and thermal performance that drive financial, environmental, and work-space benefits for a wide variety of customers, including nearly 40% of the Fortune 500.

Twitter:            @OrionLighting and @OrionLightingIR
StockTwits:      @Orion_LED_IR

Investor Relations Contacts:
Bill Hull, CFO
Orion Energy Systems, Inc.
(312) 660-3575 or ir@oesx.com

William Jones; Tanya Kamatu
Catalyst IR
(212) 924-9800 or oesx@catalyst-ir.com

$CPRX Prices Previously Announced Public Offering of Common Stock

$ASCMA to Present at Upcoming Conferences

$OHGI CEO Mark White Provides Update to Shareholders

LONDON, Nov. 28, 2017 – One Horizon Group, Inc. (NASDAQ:OHGI) issued the following letter to shareholders today from Mark White, Chief Executive Officer.

Dear Fellow Shareholders –

In writing this letter, I would like to begin by sharing my gratitude for each of you and my confidence and pride in the future of One Horizon Group.

I am the first to recognize that in the past few months, our Company has undergone profound change and I want to share with you a few words about my vision for our bright future.

As One Horizon Group’s Founder and CEO, my conviction that we must succeed derives from the responsibility I personally embrace to lead our Company’s strategy to identify, acquire and integrate businesses that will allow us to lead the next wave of cutting edge technologies driving the growth of disruptive social media, on-demand video, gaming, education, security and electronic commerce mobile applications.  We will integrate the target acquisitions with our existing business, streamlining operational efficiencies and increasing profitability.

There are tremendous opportunities within our sights to acquire Asia-based businesses ready to launch their operations globally as well as European and United States-based businesses that are recognized leaders in their respective areas, poised to expand into large markets including China with the international expertise and guidance of our team.

Consumer behavior is shifting at a rapid pace and we are positioned at the intersection of great innovation.  Our shift in strategy is based on significant diligence and we expect to have a front-row seat at the convergence of the physical and digital worlds that will drive unprecedented business opportunities for One Horizon Group.  Although our ambitions may appear grand, we are laser focused on execution and I am confident we will achieve our goals.

As we advance our Company in the marketplace as a forward-thinking technology acquisition business, I recognize that beyond these exciting technologies, platforms and content we will acquire, we must deliver unique value propositions to our customers.  I see a future where our technologies will make lives more exciting, our platforms will be inviting and easy to use, and our content will be unique and desirable.  We have done our homework and we will not be reinventing the wheel; our target acquisitions are already capturing the hearts, minds and finances of significant population groups spanning multiple continents.

For a moment, I would like to talk about people.  It has been said that “leadership is a conversation.”  Many years ago, I learned that by listening to my customers, colleagues and shareholders, I might hear new ideas that could help us improve our Company.  I am proud to be working with a great team including Edwin Lun, Chief Operating Officer, and Martin Ward, Chief Financial Officer.  We plan to regularly communicate with our customers and shareholders.

We will be measured by our innovation, our sales, our profitability, our corporate responsibility, our social impact, and our share price, but we will always maintain our core values.  I am deeply aware that our stock price is an important measure of the progress that we make in the weeks, months and years to come.  The catalyst for this progress will be completing strategic acquisitions that build our capabilities to deliver exponential returns to our shareholders by accelerating the reach of technologies, platforms and content to large numbers of subscribers, users and I expect, raving fans.

While quarterly and annual reports and future updates will quantify our success, I will be taking measure daily so we can anticipate areas of challenge and mobilize our team to take clear and decisive actions that will deliver results.  It is in these details that we will harness the driving force that will take One Horizon Group to the next level.

Thank you all deeply for your support and for joining us on this evolution.

Warm regards,

Mark White
CEO, One Horizon Group, Inc.

About One Horizon Group, Inc.

One Horizon Group, Inc. (NASDAQ:OHGI) is a reseller of secure messaging software for the growing gaming, security and education markets including in China and Hong Kong.  For more information on the Company please visit http://www.onehorizongroup.com/investors-overview/.

Darrow Associates Contacts for OHGI

Bernie Kilkelly
(516) 236-7007
bkilkelly@darrowir.com

Jordan Darrow
(512) 551-9296 
jdarrow@darrowir.com

$VERI Among the First to Be Recognized by AWS for Machine Learning Expertise

COSTA MESA, Calif.

Veritone®, Inc. (NASDAQ: VERI), a leading provider of artificial intelligence (AI) insights and cognitive solutions, today announced that it has achieved Amazon Web Services (AWS) Machine Learning (ML) Competency status. This designation recognizes Veritone for offering solutions that enable prescriptive and predictive capabilities within customer workflows and applications.

AWS ML Competency status designates Veritone as an AWS Partner Network (APN) member that has built solutions that help organizations solve their data challenges, enable machine learning and data science workflows or offer SaaS/API-based capabilities that enhance end applications with machine intelligence. Attaining the AWS ML Competency demonstrates to Veritone’s customers that the company has ML expertise on AWS.

“Achieving AWS ML Competency status recognizes Veritone’s proven track record of making AI accessible and actionable to institutions and organizations by combining the most advanced processing engines across major cognitive functions with a suite of powerful applications and a proprietary orchestration layer informed by machine learning,” said Chad Steelberg, chairman and chief executive officer of Veritone. “Our team is dedicated to helping customers achieve their business goals by uncovering previously-unavailable intelligence and by leveraging the agility of AWS.”

AWS is enabling scalable, flexible, and cost-effective solutions for startups to global enterprises. To support the seamless integration and deployment of these solutions, AWS established the AWS Partner Competency Program to help customers identify Consulting and Technology APN Partners with deep industry experience and expertise.

“Given the complexity of building a scalable and reliable production workflow that serves billions of predictions, deploying machine learning at scale is still a challenge,” said Joseph Spisak, global lead for artificial intelligence and machine learning partnerships, Amazon Web Services, Inc. “We are thrilled to have Veritone join us as an APN Partner for the Artificial Intelligence and Machine Learning Competency Program. By automating routine tasks, teams are able focus squarely on the problems they are trying to solve and spend less time worrying about how to optimize and deploy their models.”

The first commercially-available AI operating system, the Veritone aiWARE™ platform is available on AWS Marketplace. As an APN Advanced Technology Partner in the AWS Partner Network (APN), Veritone provides AWS customers with full access to aiWARE, enabling the index and search of unstructured data to derive actionable business insights.

About Veritone

Veritone (NASDAQ: VERI) is a leading artificial intelligence company that has developed a unique platform, aiWARE, which unlocks the power of AI-based cognitive computing to transform and analyze unstructured public and private audio and video data for clients in a variety of markets, including media, politics, legal and government. The open platform integrates an ecosystem of best-of-breed cognitive engines and powerful applications, which can be orchestrated together to reveal valuable, multivariate insights. aiWARE delivers unprecedented insights by unlocking data from linear files such as radio and TV broadcasts, surveillance footage and public and private content globally. To learn more about Veritone, please visit Veritone.com.

Safe Harbor Statement

This news release contains forward-looking statements, including without limitation statements regarding Veritone’s listing on the AWS Marketplace, its status as an Advanced Technology Partner in the AWS Partner Network, the recognition of its artificial intelligence / machine learning competency, and the use of the Veritone aiWARE platform by AWS users and the expected benefits. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Assumptions relating to the foregoing involve judgments and risks with respect to various matters which are difficult or impossible to predict accurately and many of which are beyond the control of Veritone. Certain of such judgments and risks are discussed in Veritone’s SEC filings. Although Veritone believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the results contemplated in forward-looking statements will be realized. In light of the significant uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by Veritone or any other person that their objectives or plans will be achieved. Veritone undertakes no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

BLASTmedia for Veritone, Inc.
Meghan Matheny, 317-806-1900 x115
meghan_matheny@blastmedia.com

$ZN Receives Multi-Year Extension on Megiddo-Jezreel License

Zion Prepares to Resume Drilling Operations

DALLAS and CAESAREA, Israel, Nov. 27, 2017 — Zion Oil & Gas, Inc. (NASDAQ: ZN) is pleased to announce that on November 20^th, 2017 Zion received a two-year extension on its Megiddo-Jezreel License No. 401, extending its validity to December 2, 2019.  Zion’s CEO, Victor Carrillo, expresses his optimism, “During this season of thanksgiving, we are especially grateful that Israel’s Petroleum Commissioner has granted Zion a multi-year extension that validates the years of work and accomplishments on the license. This multi-year extension should assure investors that our current well will continue unabated, without the risk that the Energy Ministry would ‘pull our license.’ Since I joined the company in 2011, I’ve seen no multi-year license extensions, as any extension is typically only one year at a time.  Zion’s proven track record of continued exploration in Israel, and our history of fulfilling our obligations to the State of Israel, give confidence to the current Petroleum Commissioner to grant us this multi-year license extension.”

Zion’s President, Dustin Guinn, says, “We have received on location most of the equipment that was ordered to allow us to prepare to resume drilling operations soon.  While it has been a patience-testing delay, I would like to reiterate that it was one that was necessary to maintain the integrity of the wellbore which will allow Zion to safely continue drilling deeper.  I am very excited about resuming drilling operations.  We have begun rigging up the equipment that has arrived on location and once all are inspected and tested we will run back in the hole and resume drilling.  As we approach what I believe is the most exciting section of the well, we ask that you continue to pray for safe operations throughout the drilling and testing of the well.”

Click Here to Learn More About Unit Program

FORWARD-LOOKING STATEMENTS: Statements in this communication that are not historical fact, including statements regarding Zion’s planned operations, geophysical and geological data and interpretation, anticipated attributes of geological strata being drilled, the presence or recoverability of hydrocarbons, operational risks in testing and well completion, the sufficiency of cash reserves, ability to raise additional capital, timing and potential results thereof and plans contingent thereon are forward-looking statements as defined in the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on assumptions that are subject to significant known and unknown risks, uncertainties and other unpredictable factors, many of which are described in Zion’s periodic reports filed with the SEC and are beyond Zion’s control. These risks could cause Zion’s actual performance to differ materially from the results predicted by these forward-looking statements. Zion can give no assurance that the expectations reflected in these statements will prove to be correct and assumes no responsibility to update these statements.

Contact Info:
Zion Oil & Gas, Inc. (NASDAQ: ZN)
12655 North Central Expressway, Suite 1000, Dallas, TX 75243
Andrew Summey
Telephone: 888-891-9466
Email: andrew.summey@zionoil.com
www.zionoil.com

$MTBC Announces Signing of Its Largest Client, a 950 Provider Group

SOMERSET, N.J., Nov. 27, 2017 — MTBC (NASDAQ:MTBC) (NASDAQ: MTBCP), a leading provider of mHealth and cloud-based clinical and practice management solutions, today announced the signing of a 950 provider multi-state therapy group, which is expected to ramp-up by the end of 2017 to become the client generating MTBC’s largest monthly revenue.

“We’re honored that one of the nation’s largest and most innovative clinician-owned providers of physical, occupational and speech therapy services has selected MTBC,” said Karl Johnson, MTBC SVP Sales and Marketing. “With their unique practice emphasis, and exceptional rate of sustained growth, they’ll be leveraging our integrated solution to support continued growth and scale.”

“We will begin providing services to our new client this month and expect to be generating initial revenue during fourth quarter 2017,” said Stephen Snyder, MTBC President.  “As we begin 2018, this new relationship will likely represent our largest single source of monthly client revenue.”

Under the service agreement entered into by the parties on November 21^st, MTBC will be providing revenue cycle management services and personnel support.  MTBC will also be making available its industry leading platform and practice management solution.

About MTBC

MTBC is a healthcare information technology company that provides a fully integrated suite of proprietary web-based solutions, together with related business services, to healthcare providers throughout the United States. Our integrated Software-as-a-Service (SaaS) platform helps our customers increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. MTBC’s common stock trades on the NASDAQ Capital Market under the ticker symbol “MTBC,” and its Series A Preferred Stock trades on the NASDAQ Capital Market under the ticker symbol “MTBCP.”

For additional information, please visit our website at www.mtbc.com.

Follow MTBC on TWITTER, LINKEDIN and FACEBOOK.

Forward-Looking Statements
This press release contains various forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “goals”, “intend”, “likely”, “may”, “plan”, “potential”, “predict”, “project”, “will” or the negative of these terms or other similar terms and phrases.

Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Forward-looking statements in this press release include, without limitation, statements reflecting management’s expectations for future financial performance and operating expenditures, expected growth, profitability and business outlook, the ramp-up, revenue and retention of new and existing clients, increased sales and marketing expenses, and the expected results from the integration of our acquisitions.

Forward-looking statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from those anticipated by such statements. These factors include, but are not limited to, the company’s ability to manage growth; integrate acquisitions; effectively transition, ramp-up, and retain new and existing customers; comply with controlling contractual obligations and legal requirements; and other important risks and uncertainties referenced and discussed under the heading titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. Although we believe that the expectations reflected in the forward-looking statements contained in this press release are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not assume any obligations to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

SOURCE MTBC

Company and Investor Contact:
Bill Korn
Chief Financial Officer
Medical Transcription Billing, Corp. 
bkorn@mtbc.com 
(732) 873-5133

$NEPT Extends Global MaxSimil® Licence To Cannabis-Derived Products

Neptune Wellness Solutions
Mario Paradis
VP & CFO, Neptune
m.paradis@neptunecorp.com
1.450.687.2262 x236

Investor Relations Contact
(Canada)
Pierre Boucher
MaisonBrison
1.514.731.0000
pierre@maisonbrison.com

Investor Relations Contact
(U.S.)
Ed McGregor/Jody Burfening
LHA, IR
1.212.838.3777
emcgregor@lhai.com